Oxford Biomedica has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Center (VMIC) to manufacture viral vector-based vaccines.

The VMIC will provide manufacturing equipment to scale up the manufacturing of AstraZeneca’s COVID-19 vaccine, AZD1222.

The agreement may be expanded for Oxford Biomedica to provide manufacturing capacity for other novel viral-vector vaccine candidates.